BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

PerkinElmer, Inc. (PKI) And BioImage A/S Announce Collaboration For Cell-Based Screening Applications


10/19/2005 5:11:41 PM

Boston, Mass and Copenhagen, Demark – PerkinElmer Inc. (NYSE: PKI), a leading provider of drug discovery, life science research, and analytical solutions, today announced plans to collaborate with BioImage to develop cell-based assays on the PerkinElmer EnVision™ HTS multilabel plate reader platform. The commercial terms of the collaboration were not disclosed. Based in Denmark, BioImage is a leader in using protein translocation based technology to identify novel therapeutics.

The collaboration combines the BioImage assay technology with the PerkinElmer EnVision detection platform to develop a series of cell based screening methods. BioImage has developed a suite of assay technologies for measuring protein-protein interactions in living cells using PerkinElmer’s EnVision platform. The EnVision provides extremely sensitive fluorometric detection at high speeds, making it the ideal detection platform for the BioImage assays. This powerful combination enables customers to perform robust cell based identification of inhibitors of protein/protein interactions at throughput levels previously not available.

“As a leader in high-content screening and cell-based assay development, BioImage has an excellent skill base and holds a strong IP position in this space,” said Peter Coggins, Ph.D., president, PerkinElmer Life and Analytical Sciences.

“This agreement provides a logical avenue for us to commercialize some of our technologies and collaborate with the leading provider of plate readers in the HTS market,” said Dr. Patrik Dahlén, CEO of BioImage. “We are actively out-licensing our IP estate and marketing our assay development services, and are confident that the assays validated on the EnVision platform will be of great interest to many bio-pharmaceutical companies.”

For more information, contact:
PerkinElmer Life and Analytical Sciences
549 Albany Street, Boston, MA, 02118, USA
Telephone: (800) 762-4000 (U.S. Only) or +1 (617) 482-9595
Fax: +1 (617) 482-1380
Website: www.perkinelmer.com/lifesciences.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES